Citi Resumes SXC Health Solutions Coverage: PT to $120, Reiterates Buy

Citi resumed its coverage of SXC Health Solutions

on Friday after the company completed its merger with Catalyst Health Solutions effective July 2. Citi raised its SXC Health Solutions price target from $84 to $120 and reiterated its Buy rating. In the report, Citi stated, "We continue to believe SXCI's unique business model that includes Healthcare IT, combined with CHSI's centers of excellence, will resonate with mid-size and increasingly Fortune 500 clients." Shares of SXC Health Solutions were trading at $96.43 at the time of posting, up 0.06% from Thursday's market close.